Desar IME - Search Results

1

Prognostic Factors in Epithelioid Hemangioendothelioma: Analysis of a Nationwide Molecularly/Immunohistochemically Confirmed Cohort of 57 Cases.

Tomassen T, Versleijen-Jonkers YMH, Hillebrandt-Roeffen MHS, Van Cleef PHJ, van Dalen T, Weidema ME, Desar IME, Flucke U, van Gorp JM. Tomassen T, et al. Among authors: desar ime. Cancers (Basel). 2023 Jun 23;15(13):3304. doi: 10.3390/cancers15133304. Cancers (Basel). 2023. PMID: 37444414 Free PMC article.

2

'I thought I had fibroids, and now I don't': a mixed method study on health-related quality of life in uterine sarcoma patients.

den Hollander D, Lidington E, Singer S, Sodergren SC, Salah S, Fiore M, Benson C, Desar IME, Burgers VWG, Husson O, van der Graaf WTA. den Hollander D, et al. Among authors: desar ime. Health Qual Life Outcomes. 2022 Apr 20;20(1):65. doi: 10.1186/s12955-022-01971-5. Health Qual Life Outcomes. 2022. PMID: 35443673 Free PMC article.

3

Reply letter to: pitfalls and limitations of a single-centre, retrospectively derived prognostic score for phase I oncology trial participant - reply to Füssenich et al.: a new, simple and objective prognostic score for phase I cancer patients.

van Herpen CM, Teerenstra S, Desar IM, van der Graaf WT. van Herpen CM, et al. Eur J Cancer. 2012 Mar;48(4):597-8. doi: 10.1016/j.ejca.2012.01.020. Eur J Cancer. 2012. PMID: 22338604 No abstract available.

4

Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT.

Boers-Sonderen MJ, de Geus-Oei LF, Desar IM, van der Graaf WT, Oyen WJ, Ottevanger PB, van Herpen CM. Boers-Sonderen MJ, et al. Target Oncol. 2014 Dec;9(4):339-47. doi: 10.1007/s11523-014-0309-x. Epub 2014 Mar 1. Target Oncol. 2014. PMID: 24577626 Clinical Trial.

5

A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).

Grünwald V, Desar IM, Haanen J, Fiedler W, Mouritzen U, Olsen MW, van Herpen CM. Grünwald V, et al. Acta Oncol. 2011 Jan;50(1):121-6. doi: 10.3109/0284186X.2010.509104. Acta Oncol. 2011. PMID: 21174612 Clinical Trial.

6

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer.

Banerji U, Camidge DR, Verheul HM, Agarwal R, Sarker D, Kaye SB, Desar IM, Timmer-Bonte JN, Eckhardt SG, Lewis KD, Brown KH, Cantarini MV, Morris C, George SM, Smith PD, van Herpen CM. Banerji U, et al. Clin Cancer Res. 2010 Mar 1;16(5):1613-23. doi: 10.1158/1078-0432.CCR-09-2483. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179232 Free article. Clinical Trial.

7

A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.

Desar IM, Timmer-Bonte JN, Burger DM, van der Graaf WT, van Herpen CM. Desar IM, et al. Br J Cancer. 2010 Nov 23;103(11):1637-43. doi: 10.1038/sj.bjc.6605777. Epub 2010 Nov 2. Br J Cancer. 2010. PMID: 21045832 Free PMC article. Clinical Trial.

8

Early Evaluation of Response Using ¹⁸F-FDG PET Influences Management in Gastrointestinal Stromal Tumor Patients Treated with Neoadjuvant Imatinib.

Farag S, Geus-Oei LF, van der Graaf WT, van Coevorden F, Grunhagen D, Reyners AKL, Boonstra PA, Desar I, Gelderblom H, Steeghs N. Farag S, et al. J Nucl Med. 2018 Feb;59(2):194-196. doi: 10.2967/jnumed.117.196642. Epub 2017 Sep 28. J Nucl Med. 2018. PMID: 28970330 Free article.

9

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.

van der Biessen DAJ, Gietema JA, de Jonge MJA, Desar IME, den Hollander MW, Dudley M, Dunbar M, Hetman R, Serpenti C, Xiong H, Mittapalli RK, Timms KM, Ansell P, Ratajczak CK, Shepherd SP, van Herpen CML. van der Biessen DAJ, et al. Among authors: desar ime. Invest New Drugs. 2018 Oct;36(5):828-835. doi: 10.1007/s10637-017-0551-z. Epub 2018 Jan 8. Invest New Drugs. 2018. PMID: 29313279 Free PMC article. Clinical Trial.

10

Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas.

Vlenterie M, Oyen WJ, Steeghs N, Desar IME, Verheijen RB, Koenen AM, Grootjans W, DE Geus-Oei LF, VAN Erp NP, VAN DER Graaf WT. Vlenterie M, et al. Among authors: desar ime. Anticancer Res. 2019 Mar;39(3):1309-1316. doi: 10.21873/anticanres.13243. Anticancer Res. 2019. PMID: 30842163

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

144 results

Search Page